| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC1115 |
| Trial ID | JPRN-jRCT2013210008 |
| Disease | Diffuse Large B-Cell Lymphoma | Primary Mediastinal B-Cell Lymphoma | Follicular Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KTE-C19 |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | A phase3b study of KTE-C19 (at the time of manufacture of commercially available products) in patients with the indication on the package insert |
| Year | 2021 |
| Country | Japan |
| Company sponsor | Gilead Sciences, K.K. |
| Cohort 1 | |||||||
|
|||||||